Clinical trial VIOLETTE
A Phase II, Open Label, randomized, Multi-center Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination with Olaparib versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR-Related Genes (including BRCA 1/2) (VIOLETTE)
| Cancers | |
|---|---|
| Organ | Breast |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 2 |
| Academic trial | Non |
| Sponsor | AstraZeneca |
| EudraCT Identifier | 2017-002361-22 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03330847 |
| Inclusion criteria | Progressive. At least 1 line of athracycline and/or taxane |
| Last update |